ArticleBritish journal of cancer2003
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01938833 (A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.
- The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.BMC cancer · 2013Pooled it
- A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.Breast cancer research and treatment · 2013Trial
- Reprogramming the Immune Landscape of Inflammatory Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A Novel Patient-Derived Xenograft Model of Inflammatory Breast Cancer.Research square · 2026Article
- Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis.Neuro-oncology · 2026Article
- CCR7 immune cell receptor expression in inflammatory breast cancer.Scientific reports · 2026Article
- A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer.Cancer research · 2024Article
- Differential Gene Expression of fresh tissue and patient-derived explants' matricellular proteins augment inflammatory breast cancer metastasis: the possible role of IL-6 and MCP-1.QJM : monthly journal of the Association of Physicians · 2023Article
- Metadherin Regulates Inflammatory Breast Cancer Invasion and Metastasis.International journal of molecular sciences · 2023Article
- Geometric tumor embolic budding characterizes inflammatory breast cancer.Breast cancer research and treatment · 2023Article
- Quercetin activates vitamin D receptor and ameliorates breast cancer induced hepatic inflammation and fibrosis.Frontiers in nutrition · 2023Article
- Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer.Communications biology · 2021Article
- Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis.Oncogenesis · 2021Article
- In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.Biotechnology and bioengineering · 2020Article
- EMT, MET, Plasticity, and Tumor Metastasis.Trends in cell biology · 2020Review
- PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.Frontiers in oncology · 2020Article
- Toward precision medicine in inflammatory breast cancer.Translational cancer research · 2019Review
- Pathological and molecular characteristics of inflammatory breast cancer.Translational cancer research · 2019Review
- Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines.BMC cancer · 2019Article
- Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.Breast cancer research : BCR · 2019Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Improved understanding of the mechanisms responsible for the differences between IBC and non-IBC might provide novel therapeutic targets. We studied 35 consecutive patients with IBC, biopsied prior to the initiation of chemotherapy. Angiogenesis was evaluated by Chalkley counting and by assessment of endothelial cell proliferation (ECP) and vessel maturity. The presence of fibrin, expression of the hypoxia marker carbonic anhydrase IX (CA IX) and epithelialcadherin (E-cadherin) expression were immunohistochemically detected. The same parameters were obtained in a group of 104 non-IBC patients. Vascular density, assessed by Chalkley counting (P<0.0001), and ECP (P=0.01) were significantly higher in IBC than in non-IBC. Abundant stromal fibrin deposition was observed in 26% of IBC and in only 8% of non-IBC (P=0.02). Expression of CA IX was significantly less frequent in IBC than in non-IBC with early metastasis (P=0.047). There was a significant positive correlation between the expression of CA IX and ECP in IBC (r=0.4, P=0.03), implying that the angiogenesis is partly hypoxia driven. However, the higher ECP in IBC and the less frequent expression of CA IX in IBC vs non-IBC points at a role for other factors than hypoxia in stimulating angiogenesis. Strong, homogeneous E-cadherin expression was found at cell-cell contacts in all but two IBC cases, both in lymphovascular tumour emboli and in infiltrating tumour cells, challenging our current understanding of the metastatic process. Both the intense angiogenesis and the strong E-cadherin expression may contribute to the highly metastatic phenotype of IBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.